We demonstrate that enhancing PSA-NCAM expression and targeting ES-GluN2B may offer therapeutic strategies to promote synaptic anchoring of GluN2B, mitigate synaptic dysfunction, and rescue cognitive decline in AD. This evidence concerns the gene NCAM1 and Alzheimer disease.